GLP-1 receptor agonists like semaglutide and tirzepatide cause modest bone mineral density declines proportional to weight loss, primarily through mechanical unloading as patients shed pounds. However, preclinical research reveals these drugs may simultaneously exert protective osteoanabolic effects directly on bone tissue, creating a complex risk-benefit profile. This paradox challenges the longstanding assumption that obesity protects bones through mechanical loading. Modern evidence shows obese individuals actually experience qualitative bone deterioration and site-specific fracture risks despite higher bone density readings. The clinical implications extend beyond simple weight management. As millions adopt GLP-1 therapies for dramatic weight loss, skeletal monitoring becomes critical, particularly for older adults and postmenopausal women already at fracture risk. The research advocates for resistance training, optimized protein intake, and calcium/vitamin D supplementation as essential companions to weight loss interventions. This represents a paradigm shift from weight-centric to body composition-focused obesity treatment. The finding is particularly relevant given the explosive adoption of GLP-1 drugs and suggests current prescribing practices may need skeletal health safeguards to prevent long-term fragility fractures in successful weight loss patients.